Proteomic Analysis of the Retina

视网膜的蛋白质组学分析

基本信息

项目摘要

DESCRIPTION (provided by applicant): Despite several decades of studies, the mechanisms that regulate photoreceptor outer segment assembly remain largely unknown. The focus of my laboratory is to understand how the interactions between the retinal pigment epithelium (RPE) and the neural retina regulate outer segment assembly. In our previous studies of the Xenopus laevis embryonic retina, we have shown that removal of the RPE not only disrupts outer segment assembly, but also differentially regulates the protein expression profiles of both photoreceptors and Muller cells. We have also identified factors that, when added to culture, can mimic the presence of the RPE, allowing for normal outer segment assembly and normal retinal protein expression profiles. To facilitate and expedite the delineation of the mechanisms underlying the complex process of photoreceptor outer segment assembly, during the requested grant period, we will incorporate two-dimensional (2-D) separation of proteins followed by matrix-assisted laser desorption ionization time-of-flight (MALDI-ToF) mass spectrometry into our experimental strategies. We propose to use these powerful proteomic tools to compare the protein expression profiles of the retina, i.e., the retinal proteome, of Xenopus laevis eyes under four well-characterized experimental conditions (differential proteomics): the control whole RPE-neuroretinal proteome; that of RPEdeprived retinas with disorganized outer segments; that of retinas cultured in the presence of a nonmetabolizable glycan that supports normal outer segment assembly ("permissive" glycan) as a positive control; and that of retinas exposed to a "non permissive" glycan, to control for false positives. Inter-gel variability will be minimized and reproducibility enhanced by using 2D Differential In-Gel Electrophoresis (2D-DIGE) and the ETTANtwelve multicasting gel system. Proteins that are up- or downregulated under the different conditions will be identified MALDI-ToF MS, categorized by cluster analysis, and subsequently characterized. We predict that: (1) the majority of the differentially regulated proteins will cluster within three functional groups (cell adhesion molecules, cytoskeletal proteins, and intracellular signaling pathways); and (2) that the majority of the involved proteins will be expressed in photoreceptors and Muller cells. Therefore, we will use these criteria to prioritize our analysis of the differentially regulated proteins. We will then determine if selected target proteins that fulfill these criteria are necessary and sufficient to support outer segment assembly by down regulating their expression using a Morpholino gene knockdown approach followed by quantification of outer segment organization. Our approach will allow us to identify any functional group and/or novel protein that are sufficient for photoreceptor outer segment assembly. These studies will also generate the framework for future project periods in which the precise molecular mechanisms and detailed pathways that control photoreceptor outer segment assembly will be determined.
描述(由申请人提供):尽管进行了几十年的研究,但调节感光细胞外节组装的机制在很大程度上仍然未知。本实验室的重点是了解视网膜色素上皮细胞(RPE)和神经视网膜之间的相互作用如何调节外节组装。在我们以前的非洲爪蟾胚胎视网膜的研究中,我们已经表明,去除的RPE不仅破坏外段组装,而且差异调节光感受器和穆勒细胞的蛋白质表达谱。我们还鉴定了当加入培养物中时可以模拟RPE存在的因子,从而允许正常的外节组装和正常的视网膜蛋白表达谱。为了促进和加快光感受器外节组装的复杂过程的机制的描绘,在所要求的资助期间,我们将结合蛋白质的二维(2-D)分离,然后通过基质辅助激光解吸电离飞行时间(MALDI-ToF)质谱到我们的实验策略。我们建议使用这些强大的蛋白质组学工具来比较视网膜的蛋白质表达谱,即,视网膜蛋白质组,非洲爪蟾眼睛在四个良好的表征实验条件(差异蛋白质组学):对照全RPE-神经视网膜蛋白质组; RPE剥夺视网膜与紊乱的外节;视网膜中培养的非代谢聚糖,支持正常的外节组装在一些实施方案中,将暴露于“非容许”聚糖的视网膜的糖链(“容许”聚糖)作为阳性对照;以及将暴露于“非容许”聚糖的视网膜的糖链作为阳性对照,以控制假阳性。通过使用2D差示凝胶内电泳(2D-DIGE)和ETTANtwelve多播凝胶系统,将最大限度地降低凝胶间变异性并提高重现性。在不同条件下上调或下调的蛋白质将通过MALDI-ToF MS进行鉴定,通过聚类分析进行分类,随后进行表征。我们预测:(1)大多数差异调节的蛋白质将聚集在三个功能组(细胞粘附分子、细胞骨架蛋白和细胞内信号传导途径)内;和(2)大多数涉及的蛋白质将在光感受器和Muller细胞中表达。因此,我们将使用这些标准来优先考虑我们的差异调节蛋白的分析。然后,我们将确定满足这些标准的所选靶蛋白是否是必要的和足够的,以通过使用吗啉代基因敲低方法下调其表达,然后定量外节组织来支持外节组装。我们的方法将使我们能够确定任何功能组和/或新的蛋白质,足以感光体外节组装。这些研究还将为未来的项目周期产生框架,其中将确定控制光感受器外节组装的精确分子机制和详细途径。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MONICA M JABLONSKI其他文献

MONICA M JABLONSKI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MONICA M JABLONSKI', 18)}}的其他基金

Novel Extended Release Glaucoma Therapy for Once Daily Dosing
每日一次给药的新型青光眼缓释疗法
  • 批准号:
    9912475
  • 财政年份:
    2020
  • 资助金额:
    $ 14.26万
  • 项目类别:
Novel Extended Release Glaucoma Therapy for Once Daily Dosing
每日一次给药的新型青光眼缓释疗法
  • 批准号:
    10374760
  • 财政年份:
    2020
  • 资助金额:
    $ 14.26万
  • 项目类别:
Novel Extended Release Glaucoma Therapy for Once Daily Dosing
每日一次给药的新型青光眼缓释疗法
  • 批准号:
    10597097
  • 财政年份:
    2020
  • 资助金额:
    $ 14.26万
  • 项目类别:
Novel Extended Release Glaucoma Therapy for Once Daily Dosing
每日一次给药的新型青光眼缓释疗法
  • 批准号:
    10542485
  • 财政年份:
    2020
  • 资助金额:
    $ 14.26万
  • 项目类别:
Genetic Modulation of Glaucoma
青光眼的基因调控
  • 批准号:
    8473870
  • 财政年份:
    2011
  • 资助金额:
    $ 14.26万
  • 项目类别:
Genetic Modulators of Glaucoma
青光眼的遗传调节剂
  • 批准号:
    10361394
  • 财政年份:
    2011
  • 资助金额:
    $ 14.26万
  • 项目类别:
Genetic Modulation of Glaucoma
青光眼的基因调控
  • 批准号:
    8927763
  • 财政年份:
    2011
  • 资助金额:
    $ 14.26万
  • 项目类别:
Genetic Modulation of Glaucoma
青光眼的基因调控
  • 批准号:
    8023333
  • 财政年份:
    2011
  • 资助金额:
    $ 14.26万
  • 项目类别:
Genetic Modulation of Glaucoma
青光眼的基因调控
  • 批准号:
    8269646
  • 财政年份:
    2011
  • 资助金额:
    $ 14.26万
  • 项目类别:
Genetic Modulators of Glaucoma
青光眼的遗传调节剂
  • 批准号:
    10090598
  • 财政年份:
    2011
  • 资助金额:
    $ 14.26万
  • 项目类别:

相似海外基金

Determining how the G1/S cell cycle transition regulates the homeostasis of adult intestinal stem cells
确定 G1/S 细胞周期转变如何调节成体肠道干细胞的稳态
  • 批准号:
    9607770
  • 财政年份:
    2018
  • 资助金额:
    $ 14.26万
  • 项目类别:
Determining how the G1/S cell cycle transition regulates the homeostasis of adult intestinal stem cells
确定 G1/S 细胞周期转变如何调节成体肠道干细胞的稳态
  • 批准号:
    9899107
  • 财政年份:
    2018
  • 资助金额:
    $ 14.26万
  • 项目类别:
PROTEOLYSIS AND MAMMALIAN GL/S CELL CYCLE TRANSITION
蛋白质水解和哺乳动物 GL/S 细胞周期转变
  • 批准号:
    2871922
  • 财政年份:
    1998
  • 资助金额:
    $ 14.26万
  • 项目类别:
PROTEOLYSIS AND MAMMALIAN GL/S CELL CYCLE TRANSITION
蛋白质水解和哺乳动物 GL/S 细胞周期转变
  • 批准号:
    6800864
  • 财政年份:
    1998
  • 资助金额:
    $ 14.26万
  • 项目类别:
PROTEOLYSIS AND MAMMALIAN GL/S CELL CYCLE TRANSITION
蛋白质水解和哺乳动物 GL/S 细胞周期转变
  • 批准号:
    6350210
  • 财政年份:
    1998
  • 资助金额:
    $ 14.26万
  • 项目类别:
PROTEOLYSIS AND MAMMALIAN GL/S CELL CYCLE TRANSITION
蛋白质水解和哺乳动物 GL/S 细胞周期转变
  • 批准号:
    2628102
  • 财政年份:
    1998
  • 资助金额:
    $ 14.26万
  • 项目类别:
PROTEOLYSIS AND MAMMALIAN GL/S CELL CYCLE TRANSITION
蛋白质水解和哺乳动物 GL/S 细胞周期转变
  • 批准号:
    6150049
  • 财政年份:
    1998
  • 资助金额:
    $ 14.26万
  • 项目类别:
PROTEOLYSIS AND MAMMALIAN GL/S CELL CYCLE TRANSITION
蛋白质水解和哺乳动物 GL/S 细胞周期转变
  • 批准号:
    6497689
  • 财政年份:
    1998
  • 资助金额:
    $ 14.26万
  • 项目类别:
G1/S CELL CYCLE CONTROL IN HEMATOPOIETIC CELLS
造血细胞中的 G1/S 细胞周期控制
  • 批准号:
    2143404
  • 财政年份:
    1991
  • 资助金额:
    $ 14.26万
  • 项目类别:
G1/S CELL CYCLE CONTROL IN HUMAN HEMATOPOIETIC CELLS
人类造血细胞中的 G1/S 细胞周期控制
  • 批准号:
    3245433
  • 财政年份:
    1991
  • 资助金额:
    $ 14.26万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了